Akèy › Dyabèt Tip 2 › Virginia › Arlington
Etid klinik pou Dyabèt Tip 2 nan Arlington, VA
15 etid pou Dyabèt Tip 2 ap chèche patisipan nan sit nan ak bò kote Arlington (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event
Ap rekriteFaz 2
- Carient Heart and Vascular LLC-Reston, Reston · 14 mi lwen
- Carient Heart & Vascular - Manassas, Manassas · 22 mi lwen
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
Ap rekriteFaz 3
- Seven Corners Medical Center, Falls Church · 4 mi lwen
- Carient Heart and Vascular, Manassas · 22 mi lwen
A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
Ap rekriteFaz 3
- Research Site, Manassas · 22 mi lwen
A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
Ap rekriteFaz 3
- Research Site, Manassas · 22 mi lwen
A Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus
Ap rekriteFaz 2
- Conquest Research - Arlington, Vienna · 9 mi lwen
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
Ap rekriteFaz 3
- Manassas Clinical Research Center, Manassas · 22 mi lwen
Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)
Ap rekriteFaz 2
- Conquest Research, Vienna · 9 mi lwen
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
Ap rekriteFaz 3
- Manassas Clinical Research Center Inc, Manassas · 22 mi lwen
AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications
Ap rekriteFaz 3
- Carient Heart and Vascular, Manassas · 22 mi lwen
A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus
Ap rekriteFaz 3
- Research Site, Arlington
A Study to Identify and Characterize Patients With Type 2 Diabetes Mellitus for Possible Participation in Ongoing or Future Type 2 Diabetes Mellitus Clinical Studies
Ap rekriteEtid obsèvasyon
- Research Site, Potomac · 11 mi lwen
Study to Evaluate HM15275 in Subjects With Type 2 Diabetes Mellitus
Ap rekriteFaz 2
- Manassas Clinical Research Center, Manassas · 22 mi lwen
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin
Ap rekriteFaz 3
- Research Site, Potomac · 11 mi lwen
Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy
Ap rekriteFaz 2
- Burke Internal Medicine and Research, Burke · 11 mi lwen
HP-211 Safety and Proof of Concept Dose Ranging Study in Patients With Type 2 Diabetes
Ap rekriteFaz 2
- Burke Internal Medicine & Research, Burke · 11 mi lwen
Etid Dyabèt Tip 2 nan lòt vil
- San Antonio, TX37 etid
- Houston, TX31 etid
- Orlando, FL24 etid
- Boston, MA20 etid
- Miami, FL19 etid
- Chicago, IL19 etid
- Dallas, TX19 etid
- Columbus, OH18 etid
- Las Vegas, NV18 etid
- Atlanta, GA17 etid
- San Diego, CA17 etid
- Los Angeles, CA16 etid
Lòt etid nan Arlington
- Kansè Poumon ki pa ti selil104 etid
- Kansè Metastatik53 etid
- Kansè kolorektal52 etid
- Kansè (tout kalite)48 etid
- Kansè nan tete46 etid
- Kansè ovè46 etid
- Kansè poumon41 etid
- Kansè Endomèt39 etid
- Kansè pankreyas33 etid
- Karsinòm selil skuamèz tèt ak kou26 etid
- Kansè poumon selil ti23 etid
- Kansè tete negatif triple20 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.